ArticleFrontiers in immunology2026
Quantitative systems pharmacology model of B cell immune response in mouse.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B cell-mediated immunity plays a crucial role in long-term humoral protection. However, dysregulation of B cell development and differentiation may lead to the persistence of autoreactive clones, contributing to autoimmune diseases. Despite a number of therapeutic agents in preclinical and clinical development targeting B cell biology, several challenges still limit their successful translation into clinical use. To better understand B cell-targeting mechanisms of action quantitatively and mechanistically, we developed an integrative systems pharmacology model that describes T cell-dependent B cell response to antigen exposure in mouse. The model includes 20 ordinary differential equations representing key biological processes involved in the B lymphocyte response: B cell activation in secondary lymphoid organs; antibody-secreting cell (ASC) generation; migration to the bone marrow; and redistribution to peripheral tissues. The model adequately described ASC dynamics across tissues and IgG time profiles in plasma. Local and global sensitivity analyses identified the ASC production rate as the main contributor to cell counts in the spleen and in lymph nodes, while ASC levels in the bone marrow were primarily controlled by their influx rate, reflecting survival niche availability. Moderate variations of this influx rate parameter allowed the model to capture high inter-study variability in bone marrow ASC levels, explaining the observed heterogeneity in the functional immune response. The model can be further used as a quantitative tool to study B cell responses and their dysregulation in autoimmunity. It can be extended by integrating plasma-cell biology and autoantibody production, ultimately supporting the development of new therapeutic strategies for autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.